SPBC17G9.12c Antibody

What is SPBC17G9.12c protein and why is it studied in research?

SPBC17G9.12c is a protein found in Schizosaccharomyces pombe (strain 972/ATCC 24843), commonly known as fission yeast. The protein is identified by UniProt accession number Q9UUE0. While specific functional characterization is still ongoing, researchers study this protein to better understand various cellular processes in S. pombe, which serves as an important model organism for eukaryotic cell biology. The antibody against this protein enables visualization and quantification of SPBC17G9.12c in various experimental contexts, facilitating studies on protein expression, localization, and interaction networks within fission yeast cells .

What are the optimal storage conditions for SPBC17G9.12c antibody?

SPBC17G9.12c antibody should be stored at either -20°C or -80°C upon receipt. It's crucial to avoid repeated freeze-thaw cycles as these can degrade the antibody and reduce its efficacy in experiments. The antibody is typically supplied in a storage buffer containing 50% glycerol, 0.01M PBS at pH 7.4, and 0.03% Proclin 300 as a preservative . For working aliquots, researchers should divide the stock into small volumes to minimize freeze-thaw cycles. When handling the antibody, allow it to equilibrate to room temperature before opening the vial to prevent condensation that could introduce microbial contamination or dilute the antibody solution.

What applications has SPBC17G9.12c antibody been validated for?

SPBC17G9.12c antibody has been specifically tested and validated for Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot (WB) applications. These techniques are essential for protein detection and quantification in research settings . The antibody's specificity makes it suitable for detecting SPBC17G9.12c protein in S. pombe extracts, enabling researchers to study protein expression levels under various experimental conditions. While not explicitly tested for other applications, researchers might explore its utility in immunoprecipitation, immunofluorescence, or chromatin immunoprecipitation studies, though optimization and validation would be necessary for these applications.

What controls should be included when using SPBC17G9.12c antibody in experiments?

When designing experiments with SPBC17G9.12c antibody, proper controls are essential for result validation. At minimum, include:

• Positive control: S. pombe wild-type strain extracts known to express SPBC17G9.12c

• Negative control: Either:

  • Extracts from S. pombe knockout strains lacking SPBC17G9.12c

  • Non-relevant species extracts (e.g., S. cerevisiae) where cross-reactivity is not expected

• Secondary antibody-only control: Sample treated only with the secondary antibody to identify non-specific binding

• Isotype control: Using a non-specific rabbit IgG at the same concentration to identify non-specific binding due to the IgG itself

These controls help distinguish specific signals from background noise and validate antibody specificity, particularly important when optimizing experimental conditions or when using the antibody in applications beyond those already validated.

How can I optimize Western blot protocols specifically for SPBC17G9.12c detection in S. pombe extracts?

Optimizing Western blot protocols for SPBC17G9.12c detection requires attention to several key parameters:

Sample preparation:

• Extract proteins from S. pombe using either mechanical disruption (glass beads) or enzymatic methods (zymolyase treatment followed by gentle lysis)

• Include protease inhibitors to prevent degradation of SPBC17G9.12c

• Denature samples at 95°C for 5 minutes in standard Laemmli buffer containing SDS and β-mercaptoethanol

Electrophoresis and transfer:

• Use 10-12% polyacrylamide gels for optimal separation

• Transfer to PVDF membranes (preferred over nitrocellulose for this application)

• Use wet transfer at 30V overnight at 4°C for maximum transfer efficiency of yeast proteins

Antibody concentration and incubation:

• Block with 5% non-fat milk in TBST for 1 hour at room temperature

• Dilute SPBC17G9.12c antibody at 1:500 to 1:2000 range (optimize empirically)

• Incubate with primary antibody overnight at 4°C with gentle rocking

• Wash extensively (5 × 5 minutes) with TBST before secondary antibody incubation

• Use anti-rabbit HRP-conjugated secondary antibody at 1:5000 dilution

This optimized protocol accounts for the specific properties of S. pombe extracts and the binding characteristics of the SPBC17G9.12c antibody, enabling higher sensitivity and specificity in detection.

What strategies can address cross-reactivity issues when using SPBC17G9.12c antibody in complex S. pombe lysates?

Cross-reactivity can be a significant challenge when working with polyclonal antibodies like the SPBC17G9.12c antibody. To address this issue, implement the following strategies:

Pre-absorption technique:

• Prepare lysate from SPBC17G9.12c knockout S. pombe strains

• Incubate diluted antibody with this lysate (1:10 ratio of antibody:lysate) for 2 hours at room temperature

• Centrifuge at 14,000 × g for 15 minutes to remove antibody-antigen complexes

• Use the supernatant for your experiments

Optimization of blocking conditions:

• Test alternative blocking agents (BSA, casein, commercial blocking reagents)

• Increase blocking time from 1 hour to overnight at 4°C

• Add 0.1-0.5% Tween-20 to reduce hydrophobic interactions

Increased stringency in washing:

• Use higher salt concentration in wash buffers (up to 500 mM NaCl)

• Increase washing duration and number of washes

• Add 0.1% SDS to wash buffer for particularly problematic samples

These approaches help reduce non-specific binding while maintaining detection of the target protein, greatly improving signal-to-noise ratio in complex yeast extracts.

How can I use SPBC17G9.12c antibody for co-immunoprecipitation studies to identify protein interaction partners?

Co-immunoprecipitation (Co-IP) with SPBC17G9.12c antibody can reveal important protein interaction networks. Follow this specialized protocol:

Lysate preparation:

• Harvest mid-log phase S. pombe cells (OD600 = 0.5-0.8)

• Lyse cells in non-denaturing buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5% NP-40, 1 mM EDTA, protease inhibitors)

• Clear lysate by centrifugation at 14,000 × g for 15 minutes at 4°C

Antibody coupling:

• Couple 5-10 μg of SPBC17G9.12c antibody to 50 μl of Protein A/G magnetic beads

• Cross-link antibody to beads using BS3 or similar cross-linker to prevent antibody co-elution

Immunoprecipitation:

• Incubate prepared lysate with antibody-coupled beads for 3-4 hours at 4°C with rotation

• Wash beads extensively (5 × 5 minutes) with wash buffer (lysis buffer with reduced detergent)

• Elute complexes with gentle elution buffer or by boiling in SDS sample buffer

• Analyze by SDS-PAGE followed by silver staining or Western blotting

Mass spectrometry analysis:

• Submit samples for LC-MS/MS analysis to identify interaction partners

• Compare with control IPs (non-specific rabbit IgG) to identify specific interactions

This approach enables identification of proteins that physically interact with SPBC17G9.12c under native conditions, providing insights into its biological function and involvement in cellular pathways.

What quantitative approaches can be used to determine absolute SPBC17G9.12c protein levels using the antibody?

Absolute quantification of SPBC17G9.12c protein levels requires rigorous quantitative techniques:

Quantitative Western blotting:

• Generate a standard curve using recombinant SPBC17G9.12c protein at known concentrations (5-500 ng)

• Process standards alongside unknown samples on the same blot

• Use fluorescent secondary antibodies rather than HRP-based detection for wider linear range

• Quantify using appropriate imaging software with standard curve regression analysis

Quantitative ELISA approach:

• Develop a sandwich ELISA using SPBC17G9.12c antibody as capture antibody

• Create a standard curve using recombinant SPBC17G9.12c protein

• Apply sample dilutions that fall within the linear range of detection

• Calculate absolute protein concentration from the standard curve

Calibration table for SPBC17G9.12c quantification:

By applying these quantitative approaches, researchers can determine absolute SPBC17G9.12c protein levels in experimental samples, facilitating more precise analysis of protein expression changes across different conditions or genotypes .

How can epitope mapping be performed to characterize the binding region of SPBC17G9.12c antibody?

Epitope mapping is crucial for understanding the specific region of SPBC17G9.12c recognized by the antibody, which provides important information about antibody specificity and potential cross-reactivity. Here's a methodological approach:

Peptide array analysis:

• Generate overlapping peptides (15-20 amino acids each) spanning the entire SPBC17G9.12c sequence

• Synthesize these peptides on a membrane or microarray

• Incubate with SPBC17G9.12c antibody followed by secondary antibody detection

• Identify positive signals to pinpoint the linear epitope region

Deletion mutant analysis:

• Create a series of N-terminal and C-terminal deletion mutants of SPBC17G9.12c

• Express these recombinant proteins in an appropriate system

• Perform Western blotting with SPBC17G9.12c antibody

• Determine the smallest fragment still recognized by the antibody

Competitive binding assay:

• Pre-incubate SPBC17G9.12c antibody with candidate epitope peptides

• Apply this mixture to samples containing the full-length protein

• Measure reduction in signal to confirm epitope identity

Mutational analysis:

• Introduce point mutations within the suspected epitope region

• Test antibody binding to these mutants

• Identify critical residues required for antibody recognition

By combining these approaches, researchers can precisely define the epitope recognized by the SPBC17G9.12c antibody, which is valuable for interpreting experimental results and predicting potential cross-reactivity with related proteins.

What are the most common causes of weak or absent signal when using SPBC17G9.12c antibody in Western blots?

When encountering weak or absent signals in Western blots using SPBC17G9.12c antibody, systematically investigate these common causes:

Protein extraction issues:

• Insufficient cell lysis (especially problematic with yeast cells)

• Protein degradation during sample preparation

• Insufficient protein loading (try 30-50 μg total protein)

• Improper sample denaturation

Transfer problems:

• Inefficient transfer (optimize transfer time and buffer composition)

• Using inappropriate membrane type (PVDF recommended for this antibody)

• Air bubbles during transfer setup

Antibody-related issues:

• Antibody degradation due to improper storage

• Insufficient primary antibody concentration (try 1:500 instead of 1:2000)

• Insufficient incubation time (extend to overnight at 4°C)

• Secondary antibody mismatch or degradation

Detection issues:

• Expired ECL or detection reagents

• Insufficient exposure time

• Overused developer solutions

Systematic troubleshooting approach:

• Run a positive control (recombinant SPBC17G9.12c protein)

• Check protein transfer with reversible stain (Ponceau S)

• Test antibody using dot blot with purified protein

• Validate secondary antibody with a different primary antibody

This methodical approach allows researchers to identify and address the specific issue causing weak or absent signals when working with SPBC17G9.12c antibody.

How can I distinguish between true negative results and technical failures when using SPBC17G9.12c antibody?

Distinguishing between true negative results and technical failures requires implementing proper experimental controls and validation steps:

Essential controls to include:

• Positive sample control: Include a sample known to express SPBC17G9.12c

• Loading control: Probe for a housekeeping protein (e.g., actin or tubulin) on the same membrane

• Antibody validation control: Include recombinant SPBC17G9.12c protein

Technical validation steps:

• Perform Ponceau S staining immediately after transfer to confirm protein transfer

• Use pre-stained molecular weight markers visible during transfer and imaging

• Split your membrane and process one half with a validated antibody for another target

Analysis workflow for negative results:

By implementing this structured approach and decision tree, researchers can confidently determine whether negative results represent true biological findings or technical artifacts .

What modifications to standard protocols are needed when using SPBC17G9.12c antibody for immunofluorescence studies in fixed yeast cells?

Immunofluorescence in yeast cells presents unique challenges due to the cell wall. Here's a specialized protocol for using SPBC17G9.12c antibody in this application:

Cell fixation and wall digestion:

• Fix mid-log phase S. pombe cells with 3.7% formaldehyde for 30 minutes

• Wash cells with PBS containing 1.2M sorbitol (PBS-S)

• Digest cell wall with zymolyase (1 mg/ml) in PBS-S with 1% β-mercaptoethanol for 10-20 minutes at 37°C

• Monitor digestion by checking for spheroplast formation microscopically

Permeabilization and blocking:

• Permeabilize cells with 0.1% Triton X-100 in PBS for 5 minutes

• Block with 1% BSA, 0.1% Tween-20 in PBS for 60 minutes

Antibody incubation:

• Dilute SPBC17G9.12c antibody 1:100 to 1:200 in blocking buffer

• Incubate cells overnight at 4°C in a humid chamber

• Wash extensively with PBS (5 × 5 minutes)

• Incubate with fluorophore-conjugated anti-rabbit secondary antibody (1:500) for 1 hour at room temperature

Imaging considerations:

• Mount slides with anti-fade mounting medium containing DAPI

• Include appropriate controls (secondary-only, unrelated primary antibody)

• Use confocal microscopy for optimal signal detection

• Acquire z-stack images to capture the full cell volume

These modifications address the specific challenges of working with yeast cells, particularly the need for cell wall digestion and careful permeabilization to maintain cellular morphology while allowing antibody access to intracellular targets.

How can SPBC17G9.12c antibody be used to study protein degradation kinetics during cellular stress?

SPBC17G9.12c antibody can be effectively used to monitor protein degradation kinetics during various cellular stresses, providing insights into protein stability and turnover mechanisms:

Experimental design:

• Expose S. pombe cultures to stress conditions (heat shock, oxidative stress, nutrient deprivation)

• Add cycloheximide (100 μg/ml) to inhibit new protein synthesis

• Collect samples at defined time points (0, 15, 30, 60, 120, 240 minutes)

• Process samples for Western blot analysis using SPBC17G9.12c antibody

Quantification approach:

• Normalize SPBC17G9.12c signal to a stable loading control (e.g., actin)

• Plot normalized values against time

• Calculate protein half-life using exponential decay equation: N(t) = N₀e^(-λt)

• Compare half-lives across different stress conditions

Sample data analysis table:

This approach enables researchers to quantitatively assess how different stress conditions affect SPBC17G9.12c protein stability, potentially revealing regulatory mechanisms controlling protein turnover during cellular adaptation to stress .

What considerations are important when using SPBC17G9.12c antibody for quantitative comparisons across different experimental conditions?

When using SPBC17G9.12c antibody for quantitative comparisons, several important considerations ensure reliable and reproducible results:

Experimental design factors:

• Standardized sample preparation:

  • Use identical protein extraction methods across all samples

  • Process all samples simultaneously to minimize batch effects

  • Determine protein concentration using the same method (BCA or Bradford)

• Technical standardization:

  • Use equal protein amounts for all samples (validate with total protein stains)

  • Include recombinant SPBC17G9.12c protein standards on each gel

  • Run all comparison samples on the same gel when possible

• Antibody consistency:

  • Use the same antibody lot number throughout the study

  • Prepare fresh antibody dilutions for each experiment

  • Maintain identical incubation times and temperatures

Data analysis considerations:

• Proper normalization:

  • Normalize to housekeeping proteins (with caution, as they may vary under some conditions)

  • Consider total protein normalization methods (REVERT, Ponceau S)

  • Include multiple normalization approaches for critical experiments

• Quantification methodology:

  • Use linear range detection methods (fluorescent secondaries preferred over ECL)

  • Perform multiple technical replicates (minimum n=3)

  • Test for statistical significance using appropriate tests

• Validation strategies:

  • Confirm key findings with orthogonal methods (qPCR, mass spectrometry)

  • Perform dose-response or time-course studies to establish trend reliability

  • Consider biological replicates from independent cultures

By addressing these considerations, researchers can ensure that quantitative comparisons of SPBC17G9.12c protein levels across different experimental conditions are robust, reproducible, and biologically meaningful.

How can SPBC17G9.12c antibody be used in conjunction with CRISPR-Cas9 gene editing to study protein function?

Combining SPBC17G9.12c antibody with CRISPR-Cas9 gene editing creates powerful experimental paradigms for functional studies:

Endogenous tagging approach:

• Design CRISPR-Cas9 strategy to insert epitope tags (HA, FLAG) adjacent to SPBC17G9.12c

• Use SPBC17G9.12c antibody to validate successful tagging via Western blot

• Compare signals from SPBC17G9.12c antibody and anti-tag antibodies to confirm specificity

• Perform immunoprecipitation with either antibody to study protein interactions

Functional domain analysis:

• Create CRISPR-Cas9 mediated domain deletions or point mutations in SPBC17G9.12c

• Use SPBC17G9.12c antibody to confirm expression of modified proteins

• Analyze changes in protein localization, stability, or interactions

• Correlate molecular changes with phenotypic outcomes

Regulatable expression systems:

• Use CRISPR-Cas9 to replace endogenous SPBC17G9.12c promoter with inducible promoter

• Apply SPBC17G9.12c antibody to quantify protein expression under various induction conditions

• Develop a calibration curve relating inducer concentration to protein levels

• Identify minimal expression levels required for function

Protein dynamics studies:

• Engineer photoactivatable or FRET-compatible tags via CRISPR-Cas9

• Validate constructs using SPBC17G9.12c antibody

• Perform live-cell imaging to track protein dynamics

• Correlate with fixed-cell immunofluorescence using SPBC17G9.12c antibody

This integrated approach leverages the specificity of SPBC17G9.12c antibody with the precision of CRISPR-Cas9 gene editing to provide multifaceted insights into protein function that neither technique alone could achieve.

What are the considerations for using SPBC17G9.12c antibody in chromatin immunoprecipitation (ChIP) experiments to study DNA-protein interactions?

Using SPBC17G9.12c antibody for Chromatin Immunoprecipitation (ChIP) requires specialized optimization due to the unique challenges of chromatin structures in yeast:

Chromatin preparation:

• Crosslink S. pombe cells with 1% formaldehyde for 15 minutes at room temperature

• Quench with 125 mM glycine for 5 minutes

• Lyse cells using glass bead disruption in lysis buffer (50 mM HEPES pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, protease inhibitors)

• Sonicate chromatin to 200-500 bp fragments (optimize sonication parameters empirically)

• Check sonication efficiency by reverse-crosslinking an aliquot and running on agarose gel

Antibody optimization:

• Test multiple antibody concentrations (2-10 μg per ChIP reaction)

• Compare direct addition vs. pre-binding to protein A/G beads

• Optimize incubation time (4 hours vs. overnight)

• Consider antibody crosslinking to beads to reduce background

Controls and validation:

• Include no-antibody control (beads only)

• Use non-specific IgG control (same species and concentration)

• Include input samples (non-immunoprecipitated chromatin)

• Consider spike-in controls for quantitative ChIP

Data analysis considerations:

• Design primers for both positive and negative genomic regions

• Normalize to input DNA

• Calculate enrichment as percent of input or relative to negative regions

• Validate key findings with ChIP-qPCR before proceeding to ChIP-seq

This methodological approach addresses the specific challenges of performing ChIP with SPBC17G9.12c antibody in S. pombe, enabling researchers to investigate potential DNA-binding properties or chromatin association of this protein with high specificity and sensitivity.

How does the specificity and sensitivity of SPBC17G9.12c polyclonal antibody compare to monoclonal alternatives for research applications?

Understanding the performance differences between polyclonal SPBC17G9.12c antibody and potential monoclonal alternatives is crucial for experimental design:

Specificity comparison:

• Polyclonal SPBC17G9.12c antibody: Recognizes multiple epitopes on the target protein, potentially increasing signal strength but may show higher background or cross-reactivity with related proteins

• Monoclonal alternatives: Target single epitopes, offering higher specificity but potentially lower sensitivity; epitope masking due to protein modifications or conformational changes can result in false negatives

Sensitivity analysis:

• Polyclonal SPBC17G9.12c antibody: Generally provides higher sensitivity due to recognition of multiple epitopes; beneficial for detecting low-abundance proteins

• Monoclonal alternatives: May require signal amplification techniques for low-abundance targets but offer more consistent lot-to-lot performance

Application-specific performance:

Reproducibility considerations:

• Polyclonal SPBC17G9.12c antibody: Batch-to-batch variation can affect experimental reproducibility; entire experiments should be completed with single lots when possible

• Monoclonal alternatives: Higher consistency between production lots, better for standardized assays and long-term studies

These comparative insights help researchers select the most appropriate antibody format based on their specific experimental requirements, balancing sensitivity, specificity, and reproducibility needs.

What alternative approaches can complement or validate findings obtained using SPBC17G9.12c antibody?

Genetic validation approaches:

• Gene deletion/knockout: Create SPBC17G9.12c deletion strains to serve as negative controls for antibody specificity

• Tagged protein expression: Express epitope-tagged versions (HA, FLAG, GFP) of SPBC17G9.12c and compare localization/interaction results

• RNA interference: Deplete SPBC17G9.12c mRNA and confirm corresponding protein reduction via antibody detection

Orthogonal detection methods:

• Mass spectrometry: Use targeted proteomics to quantify SPBC17G9.12c and validate antibody-based quantification

• RNA-seq/qRT-PCR: Correlate transcript levels with protein abundance detected by the antibody

• Proximity labeling: Use BioID or APEX2 fusions to identify protein interactions and compare with co-IP results

Functional validation strategies:

• Rescue experiments: Reintroduce wild-type or mutant SPBC17G9.12c into deletion strains and assess function restoration

• Structure-function analysis: Create domain deletions and assess effects on localization or interactions

• Heterologous expression: Express SPBC17G9.12c in a different species and assess conservation of interactions

Technical validation approaches:

• Multiple antibody comparison: When available, test additional SPBC17G9.12c antibodies raised against different epitopes

• Super-resolution microscopy: Validate subcellular localization beyond the diffraction limit

• Cryo-electron microscopy: For structural studies, validate antibody-based findings with direct structural determination

By implementing these complementary approaches, researchers can build a more comprehensive understanding of SPBC17G9.12c biology while mitigating potential artifacts or limitations associated with antibody-based detection methods.

What are the recommended best practices for ensuring reproducibility when using SPBC17G9.12c antibody across different research studies?

To ensure reproducibility when working with SPBC17G9.12c antibody across different studies, researchers should implement these best practices:

Documentation and reporting:

• Record complete antibody information (manufacturer, catalog number, lot number, concentration)

• Document detailed experimental protocols including all buffer compositions

• Provide images of full blots/gels in publications, not just cropped regions of interest

• Report all optimization steps and validation experiments

Experimental standardization:

• Maintain consistent sample preparation methodologies across studies

• Establish standard curves using recombinant SPBC17G9.12c protein

• Use automated systems where possible to reduce human variability

• Implement blinded analysis for subjective assessments (e.g., immunofluorescence intensity scoring)

Controls and validation:

• Include consistent positive and negative controls across experiments

• Validate new antibody lots against previous lots before use in critical experiments

• Perform periodic specificity checks throughout long-term studies

• Archive key samples as reference standards for future comparisons

Data management:

• Maintain detailed electronic laboratory notebooks

• Store original image files with acquisition metadata

• Use consistent data analysis workflows and software versions

• Implement quality control metrics to flag potential technical issues

By adhering to these best practices, researchers can enhance the reproducibility of findings generated using SPBC17G9.12c antibody, facilitating more reliable cross-study comparisons and accelerating scientific progress in understanding this protein's function.

What emerging technologies might enhance the utility of SPBC17G9.12c antibody in future research applications?

Several emerging technologies show promise for expanding the utility of SPBC17G9.12c antibody in future research:

Single-cell protein analysis:

• Integration with microfluidic platforms for single-cell Western blotting

• Adaptation for CyTOF mass cytometry for high-dimensional protein profiling

• Application in single-cell proteomics workflows to study cell-to-cell variation

Advanced imaging technologies:

• Expansion microscopy to physically magnify samples for improved resolution

• Lattice light-sheet microscopy for high-speed 3D imaging of living cells

• STORM/PALM super-resolution microscopy for nanoscale localization

• Correlative light and electron microscopy (CLEM) to combine functional and ultrastructural information

Protein interaction technologies:

• Proximity labeling methods (TurboID, APEX) to map the local protein environment

• Integration with CRISPR screening to systematically assess genetic interactions

• Split-pool barcoding for high-throughput antibody validation across multiple conditions

Computational approaches:

• Machine learning algorithms for automated image analysis and feature detection

• Integrative multi-omics platforms combining antibody-based data with genomics/transcriptomics

• Predictive modeling of protein dynamics based on static antibody-derived data

Delivery and modification technologies:

• Antibody functionalization with photocaged or photoactivatable moieties

• Integration with optogenetic systems for spatiotemporal control

• Nanobody or small recombinant antibody fragment development for improved tissue penetration

• Conjugation to DNA barcodes for spatial transcriptomics applications